Article
  • Effect of the Viscosity of (Hydroxypropyl)methyl Cellulose on Dissolution Rate of Alfuzosin-HCl Granule Tablet
  • Kim W, Song BJ, Kim DS, Kim SJ, Lee SK, Kim HL, Lee D, Khang G
  • HPMC의 점도에 따른 염산 알푸조신 과립정제의 용출률 조절
  • 김원, 송병주, 김대성, 김수진, 이선경, 김혜린, 이동원, 강길선
Abstract
The primary objective of this work is to find the optimal condition for the granule tablet formulation of alfuzosin-HCl that aims to achieve a sustained drug release. (Hydroxypropyl)methyl cellulose (HPMC) is one of the most widely used polymer as a drug formulation and therefore has been utilized in this study as an excipient. Alfuzosin-HCl granule tablet was developed using the various viscosities of HPMC and the effects of viscosity on drug release was investigated. Fourier transform-infrared (FTIR) and X-ray diffraction (XRD) were employed to investigate the chemical structure and crystallization of alfuzosin-HCl in the formulation. We prepared the granule tablet by a direct compression method and studied the release profile in the stimulated intestinal fluid (pH 6.8). As the viscosity of HPMC increased the release of alfuzosin-HCl decreased, demonstrating that controlled release of alfuzosin-HCl can be achieved by varying the viscosity of HPMC.

본 연구는 염산 알푸조신의 서방화를 위한 과립제의 최적 구성을 찾기 위해 수행되었으며, 이에 따라 고분자의 점도에 따른 염산 알푸조신 과립정제를 제조하였다. 사용된 고분자는 경구를 통한 약물전달 시스템 설계에 가장 널리 사용되는 하이드록시프로필메틸셀룰로오스(HPMC)이며, HPMC의 팽윤성은 가장 중요한 특성으로 약물의 방출에 큰 영향을 미친다. 염산 알푸조신 과립정제의 구조변화를 확인하기 위하여 적외선분광법(FTIR)을 분석하였으며, 결정학적 특성을 알아보기 위해 X선 회절분석법(XRD)을 이용하여 분석하였다. 과립정제를 제조하여 인공장액에서의 방출거동을 알아보았으며, 본 연구를 통해 첨가제로 사용된 HPMC의 점도에 따라 모델약물인 염산 알푸조신의 방출거동을 조절할 수 있었다.

Keywords: alfuzosin-HCl; HPMC; granule tablet; drug delivery system; release behavior

References
  • 1. Patel DB, Patel NJ, Int. J. Chem. Tech. Res., 1, 985 (2009)
  •  
  • 2. McVary KT, J. Urol., 175, 35 (2006)
  •  
  • 3. Berry SJ, Coffey DS, Walsh PC, Ewing LL, J. Urol., 132, 474 (1984)
  •  
  • 4. Garraway WM, Collins GN, Lee RJ, Lancet, 338, 469 (1991)
  •  
  • 5. Hoke GP, Am. J. Med., 121, S3 (2003)
  •  
  • 6. Lee SH, J. Korean Acad. Fam. Med., 28, 193 (2007)
  •  
  • 7. Chang HS, Park CH, J. Korean Continence Society, 7, 25 (2003)
  •  
  • 8. Franklin C, Lowe MD, Clin. Ther., 26, 1701 (2004)
  •  
  • 9. Miner M, Matt T, Rosenberg, Clin. Ther., 28, 13 (2006)
  •  
  • 10. Lee JY, Choi NK, Jung SY, Kim YJ, Seong JM, Oh SJ, Park BJ, J. Prev. Med. Public Health, 42, 165 (2009)
  •  
  • 11. Chapple CR, Rev. Urol., 7, 22 (2005)
  •  
  • 12. Hellstrom WJG, Sikka SC, J. Urol., 176, 1529 (2006)
  •  
  • 13. Blouin MC, J. Cataract Refract. Surg., 33, 1227 (2007)
  •  
  • 14. Gomes NA, Pudage A, Joshi SS, Vaidya VV, Parekh SA, Tamhankar AV, Chromatographia, 69, 9 (2009)
  •  
  • 15. Mistri HN, Jangid AG, Pudage A, Rathod DM, Shrivastav PS, J. Chromatogr. B, 876, 236 (2008)
  •  
  • 16. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM, J. Pharmacol. Exp. Ther., 324, 427 (2008)
  •  
  • 17. Pattnaik S, Swain K, Mallick S, Lat. Am. J. Pharm., 28, 62 (2009)
  •  
  • 18. Liu Q, Fassihi R, Int. J. Pharm., 348, 27 (2008)
  •  
  • 19. Chung BH, Korean J. Urol., 48, 233 (2007)
  •  
  • 20. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P, Br. J. Urol., 74, 579 (1994)
  •  
  • 21. Mottet N, Bressolle F, Delmas V, Robert M, Costa P, Eur. Urol., 44, 101 (2003)
  •  
  • 22. Jeong SC, Chon SK, Jo YH, Kim MS, Lee B, Khang G, Lee HB, Polym.(Korea), 29(3), 288 (2005)
  •  
  • 23. Siepmann J, Peppas NA, Adv. Drug Deliv. Rev., 48, 139 (2001)
  •  
  • 24. Colombo P, Adv. Drug Deliv. Rev., 11, 37 (1993)
  •  
  • 25. Youn JY, Park SW, Lee SY, Kim MS, Lee B, Khang G, Lee HB, Polym.(Korea), 32(4), 322 (2008)
  •  
  • 26. Ford JL, Rubinstein MH, Hoagen JE, Int. J. Pharm., 24, 327 (1985)
  •  
  • 27. Mitchell K, Ford JL, Rubinstein MH, Armstrong DJ, Elliot PNC, Hoagen JE, Rostron C, Int. J. Pharm., 156, 49 (1997)
  •  
  • 28. Kurahashi H, Kami H, Sanada H, Chem. Pharm. Bull., 44, 829 (1996)
  •  
  • 29. Marks LS, Roehrborn CG, Gittelman M, Adult Urol., 62, 888 (2003)
  •  
  • 30. Park JH, Kim SH, Oh JM, Ahn SI, Kim YT, Jung SH, Choi JH, Lee D, Yoo I, Rhee JM, Khang G, Tissue Eng. Regen. Med., 6, 995 (2009)
  •  
  • 31. Lee BJ, et al.Galenical Pharmacy, Hanrimwon, Seoul (2004)
  •  
  • 32. Im JH, Lee YK, Huh KM, Polym.(Korea), 32(2), 143 (2008)
  •  
  • 33. Park JS, Oh JS, Oh JM, Kim YT, Lee JH, Mo JH, Lee HB, Khang G, Polym.(Korea), 32(3), 193 (2008)
  •  
  • 34. Youn JY, Ku J, Lee SY, Kim BS, Kim MS, Lee B, Khang G, Lee HB, Polym.(Korea), 31(4), 329 (2007)
  •  
  • 35. Kim DS, Seong KY, Kim W, Hong HK, Ahn SI, Park JH, Oh JM, Kim YT, Lee EY, Lee D, Rhee JM, Khang G, Tissue Eng. Regen. Med., 6, 903 (2009)
  •  
  • 36. Virtanen S, Salokangsa H, Yliruusi J, Eur. J. Pharm. Sci., 34, S27 (2008)
  •  
  • 37. Mura P, Fauucci MT, Manderioli A, Bramanti G, Ceccarelli L, J. Pharmaceut. Biomed., 18, 151 (1998)
  •  
  • 38. Williams AC, Timmins P, Lu M, Forbes RT, Eur. J. Pharm. Sci., 26, 288 (2005)
  •  
  • 39. Park JH, Ku J, Ahn SI, Lee JH, Kim YT, Kim DS, Kim W, Rhee JM, Khang G, Tissue Eng. Regen. Med., 5, 729 (2008)
  •  
  • Polymer(Korea) 폴리머
  • Frequency : Bimonthly(odd)
    ISSN 0379-153X(Print)
    ISSN 2234-8077(Online)
    Abbr. Polym. Korea
  • 2022 Impact Factor : 0.4
  • Indexed in SCIE

This Article

  • 2010; 34(3): 269-273

    Published online May 25, 2010

  • Received on Jan 8, 2010
  • Accepted on Feb 10, 2010